Skip to main content
Top
Published in: Rheumatology International 7/2013

01-07-2013 | Original Article

Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker

Authors: Sang-Hoon Lee, Eun Jung Lee, Sang Wan Chung, Ran Song, Joo-Young Moon, Sang-Ho Lee, Sung-Jig Lim, Yeon-Ah Lee, Seung-Jae Hong, Hyung-In Yang

Published in: Rheumatology International | Issue 7/2013

Login to get access

Abstract

Ankylosing spondylitis (AS) is a chronic inflammatory disease primarily involving the spine and sacroiliac joint and rarely the kidneys. This study aimed to define the clinical and histological features and biology of renal disease in AS. We reviewed the medical records of 681 patients diagnosed with AS from November 2008 to November 2009. Baseline characteristics and laboratory and urinalysis results were reviewed. We identified patients with proteinuria or hematuria and analyzed their risk factors. After providing informed consent, 6 patients underwent a renal biopsy to determine the cause of proteinuria or hematuria. Of the 681 enrolled patients, 547 were men and 134 were women; 81 % were HLA B27 positive, and 8 % had abnormal urinalysis findings (proteinuria, 5.9 %; hematuria, 2.8 %; both, 0.7 %). Incidences of peripheral arthritis and uveitis were 29 % and 18.6 %, respectively. Immunoglobulin (Ig)A and uric acid levels were significantly different between patients with and without proteinuria. Erythrocyte sedimentation rate (ESR), total cholesterol, creatinine, and C-reactive protein (CRP) levels were not statistically significantly different between the 2 groups nor were there any significant differences in IgA, uric acid, ESR, total cholesterol, creatinine, and CRP levels between patients with and without hematuria. Six patients who had >1 g/day proteinuria underwent a renal biopsy; 2 were diagnosed with IgA nephropathy, 1 with amyloidosis, and 3 with non-specific glomerulonephropathy. In the amyloidosis patient, severe proteinuria was the dominant feature. For patients with renal amyloidosis and other forms of glomerulonephritis who initially had normal creatinine levels, tumor necrosis factor (TNF)-alpha blocker therapy resolved proteinuria, but this was not the case for patients with initial renal insufficiency. Renal involvement is not a rare complication of AS, and prognoses differ depending on kidney pathology. Serum levels of uric acid and IgA may predict renal involvement in AS. In cases where abnormal urine sediment is identified, renal biopsy is required to determine prognosis and decide the treatment protocol. Baseline serum creatinine level is important for predicting treatment response.
Literature
1.
go back to reference Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(suppl 3):iii8–iii18PubMed Sieper J, Braun J, Rudwaleit M, Boonen A, Zink A (2002) Ankylosing spondylitis: an overview. Ann Rheum Dis 61(suppl 3):iii8–iii18PubMed
2.
go back to reference Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthr Rheum 41:778–799CrossRef Lawrence RC, Helmick CG, Arnett FC et al (1998) Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthr Rheum 41:778–799CrossRef
3.
4.
go back to reference Braun J, Bollow M, Remlinger G et al (1998) Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthr Rheum 41:58–67CrossRef Braun J, Bollow M, Remlinger G et al (1998) Prevalence of spondyloarthropathies in HLA-B27 positive and negative blood donors. Arthr Rheum 41:58–67CrossRef
5.
go back to reference Ng SC, Liao Z, Yu DT et al (2007) Epidemiology of spondyloarthritis in the People’s Republic of China: review of the literature and commentary. Semin Arthr Rheum 37:39–47CrossRef Ng SC, Liao Z, Yu DT et al (2007) Epidemiology of spondyloarthritis in the People’s Republic of China: review of the literature and commentary. Semin Arthr Rheum 37:39–47CrossRef
6.
go back to reference Helmick CG, Felson DT, Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthr Rheum 58:15–25CrossRef Helmick CG, Felson DT, Lawrence RC et al (2008) Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthr Rheum 58:15–25CrossRef
7.
8.
go back to reference Elewaut D, Matucci-Cerini M (2009) Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology(Oxford) 48:1029–1035CrossRef Elewaut D, Matucci-Cerini M (2009) Treatment of ankylosing spondylitis and extra-articular manifestations in everyday rheumatology practice. Rheumatology(Oxford) 48:1029–1035CrossRef
9.
go back to reference El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22:554–560 (Review) El Maghraoui A (2011) Extra-articular manifestations of ankylosing spondylitis: prevalence, characteristics and therapeutic implications. Eur J Intern Med 22:554–560 (Review)
10.
go back to reference Vilar MJP, Cury SE, Ferraz MB, Sesso R, Atra E (1997) Renal abnormalities in ankylosing spondylitis. Scand J Rheumatol 26:19–23PubMedCrossRef Vilar MJP, Cury SE, Ferraz MB, Sesso R, Atra E (1997) Renal abnormalities in ankylosing spondylitis. Scand J Rheumatol 26:19–23PubMedCrossRef
11.
go back to reference Nabokov AV, Shabunin MA, Smirnov AV (1996) Renal involvement in ankylosing spondylitis (Bechterew’s disease). Nephrol Dial Transpl 11:1172–1175CrossRef Nabokov AV, Shabunin MA, Smirnov AV (1996) Renal involvement in ankylosing spondylitis (Bechterew’s disease). Nephrol Dial Transpl 11:1172–1175CrossRef
12.
go back to reference Strobel ES, Fritschka E (1998) Reanl diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 17:524–530PubMedCrossRef Strobel ES, Fritschka E (1998) Reanl diseases in ankylosing spondylitis: review of the literature illustrated by case reports. Clin Rheumatol 17:524–530PubMedCrossRef
13.
go back to reference Singh G, Kumari N, Aggarwal A, Krishnani N, Misra R (2007) Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 34:371–373PubMed Singh G, Kumari N, Aggarwal A, Krishnani N, Misra R (2007) Prevalence of subclinical amyloidosis in ankylosing spondylitis. J Rheumatol 34:371–373PubMed
14.
go back to reference Lehtinen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52:174–176PubMedCrossRef Lehtinen K (1993) Mortality and causes of death in 398 patients admitted to hospital with ankylosing spondylitis. Ann Rheum Dis 52:174–176PubMedCrossRef
15.
go back to reference Kobak S, Oksel F, Kabasakal Y, Doganavsargil E (2007) Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 26:2191–2194PubMedCrossRef Kobak S, Oksel F, Kabasakal Y, Doganavsargil E (2007) Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients. Clin Rheumatol 26:2191–2194PubMedCrossRef
Metadata
Title
Renal involvement in ankylosing spondylitis: prevalence, pathology, response to TNF-a blocker
Authors
Sang-Hoon Lee
Eun Jung Lee
Sang Wan Chung
Ran Song
Joo-Young Moon
Sang-Ho Lee
Sung-Jig Lim
Yeon-Ah Lee
Seung-Jae Hong
Hyung-In Yang
Publication date
01-07-2013
Publisher
Springer-Verlag
Published in
Rheumatology International / Issue 7/2013
Print ISSN: 0172-8172
Electronic ISSN: 1437-160X
DOI
https://doi.org/10.1007/s00296-012-2624-9

Other articles of this Issue 7/2013

Rheumatology International 7/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine